Lillian F. Pliner MD FACP, HMDC, FAAHPM

Oncology•Livingston, NJ

Hematologic Oncology, Hospice & Palliative

Senior Medical Director, Vitas Healthcare

Join to View Full Profile

70 S Orange AveLivingston, NJ 07039
Phone+1 973-650-6595

Summary

Dr. Lillian Pliner is an oncologist in Short Hills, NJ and is affiliated with multiple hospitals in the area, including Saint Barnabas Medical Center, East Orange General Hospital, and University Hospital. She received her medical degree from Stony Brook University School of Medicine and has been in practice 37 years. She also speaks multiple languages, including French and Spanish. She specializes in hematologic oncology and hospice & palliative and is experienced in hospice and palliative care.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
Boston University Medical CenterResidency, Internal Medicine, 1980 - 1983
Stony Brook University Health Sciences Center School of MedicineClass of 1980

Certifications & Licensure

NJ State Medical License 1986 - 2025
NY State Medical License 1983 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology
American Board of Internal MedicineHospice and Palliative Medicine

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Start of enrollment: 2004 Aug 01
Completed
Phase 3
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
ACTIVE_NOT_RECRUITING
PHASE3
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone Start of enrollment: 2004 Jan 01
A Multicenter, Open-Label Single-Arm Study of Trabectedin for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment Start of enrollment: 2005 Aug 01
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
ACTIVE_NOT_RECRUITING
PHASE2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Start of enrollment: 2009 Nov 17
ACTIVE_NOT_RECRUITING
PHASE3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

38 citations
Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells.
Shyam A. Patel, Meneka A. Dave, Sarah A. Bliss, Agata B. Giec-Ujda, Margarette Bryan
Journal of Cancer Stem Cell Research. 2014-05-29
Metastatic Gastric MALT Lymphoma Masquerading as Pulmonary Infiltrates, with a Dramatic Response to Chemotherapy
Sami Samiullah, Hadi Bhurgri, Madiha Tufail, Fatima Samad, Sheenal Patel
Journal of Gastrointestinal Cancer. 2014-04-05
72 citations
Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy
Shyam A. Patel, Shakti Ramkissoon, Margarette Bryan, Lillian F. Pliner, Gabriela Dontu
Scientific Reports. 2012-11-30

Press Mentions

5 VITAS Healthcare Physicians Earn Fellow Status from the American Academy of Hospice and Palliative MedicineFebruary 28th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Member
American Academy of Hospice and Palliative Medicine - AAHPM
Member
Sigma Xi
Member

Other Languages

French, Spanish